Pharmaceutical

Novo Nordisk plans new study for CagriSema, targets 2026 submission

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from Eli Lilly.

Feb 7, 2025 - 06:00
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from Eli Lilly.
Read the original article

Tags:

Previous Article

AstraZeneca’s shares rise as it addresses China investigation

Next Article

FDA grants orphan drug status to Arbor Biotechnologies’ PH1

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

After outcry, UnitedHealthcare softens prior authorization policy for colonoscopies

After outcry, UnitedHealthcare softens prior authorizat...

Jun 2, 2023

Pfizer’s Ngenla finally secures FDA approval following a rocky road to market

Pfizer’s Ngenla finally secures FDA approval following ...

Jun 29, 2023

A physician’s Mother’s Day gift: reclaimed time with my children — and for myself

A physician’s Mother’s Day gift: reclaimed time with my...

May 13, 2023